Trick or Treat? Licorice-Induced Hypokalemia: A Case Report

Elizabeth Benge 1, Pinak Shah 1, Leo Yamaguchi 1, Vanessa Josef 1

1. Internal Medicine, Mountainview Hospital, Las Vegas, USA

Corresponding author: Elizabeth Benge, elizabeth.benge@hcahealthcare.com

Abstract

The by-products of black licorice metabolism are toxic in high concentrations. Patients who consume large quantities of black licorice are at risk of developing an acquired syndrome of apparent mineralocorticoid excess. This presents clinically as hypertension, hypernatremia, and hypokalemia. Here, we present the unique case of a 74-year-old woman with a past medical history of neurogenic orthostatic hypotension, on fludrocortisone, who presented to the emergency department with asymptomatic hypokalemia (2.4 mmol/L) as detected in outpatient laboratory studies. During her hospital stay, it was discovered that the patient was consuming excessive amounts of black licorice. With this information, the synergistic interaction of fludrocortisone and black licorice was recognized as the cause of the patient’s severe hypokalemia. The patient’s fludrocortisone was stopped and she was treated with multiple courses of potassium repletion. Upon discharge, her fludrocortisone was discontinued, and she was prescribed midodrine to treat her neurogenic orthostatic hypertension. While small amounts of black licorice are safe, excessive licorice consumption can cause severe disease. Our case presents an opportunity to appreciate the plethora of etiologies for severe hypokalemia and the importance of taking a thorough patient history to avoid potentially fatal clinical outcomes.

Introduction

As early as 2100 BC, practitioners of traditional medicine used licorice to treat maladies ranging from pain and cough, to gastrointestinal illness [1]. Unfortunately, the bioactive properties of licorice can pose a threat to modern patients [2]. The by-products of licorice metabolism inhibit renal 11-ß-hydroxysteroid dehydrogenase (11ß-HSD2) activity, decreasing the conversion of cortisol to the inactive form [3]. Consequently, endogenous plasma cortisol is available to bind to mineralocorticoid receptors for a longer period of time, creating a syndrome known as apparent mineralocorticoid excess (AME) or pseudohyperaldosteronism [3]. Thus, patients who eat licorice regularly can experience hypertension, hypernatremia, and hypokalemia [4]. Patients at risk for severe symptoms include the elderly, women, or those with pre-existing conditions such as hypokalemia, hypertension, and anorexia nervosa [5]. Here, we present a unique case of an elderly, female patient who consumed black licorice while taking fludrocortisone and subsequently developed severe hypokalemia, due to their synergistic combination.

Case Presentation

A 74-year-old woman with a significant past medical history of Parkinson’s disease (on carbidopa/levodopa) and neurogenic orthostatic hypotension presented to the emergency department for hypokalemia as directed by her outpatient provider. On presentation, the patient denied experiencing symptoms associated with hypokalemia, including weakness, fatigue, vomiting, abdominal pain, cramping and tingling in her extremities. She stated that she felt at her baseline state of health and a 12-point review of systems was negative. When reviewing her medications, she reported taking 0.1 mg of fludrocortisone twice a day at home regularly without any missed doses. The patient’s vital signs were all within normal limits upon her arrival to the hospital, with a blood pressure of 102/70 mmHg. Her physical exam did not reveal any signs of acute pathology.

Her initial lab values demonstrated severe hypokalemia, with a potassium level of 2.4 mmol/L. Her arterial blood gas revealed metabolic alkalosis. The remainder of her initial blood work, which included a complete metabolic panel and a complete blood count, was normal. The patient’s electrocardiogram showed a ventricular-paced rhythm with a heart rate of 82 beats/min without ST-segment elevations, heart blocks, or axis deviations. Her fludrocortisone was held at that time and her potassium was repleted with both 40 meq of oral potassium and 20 meq of intravenous potassium chloride. She was subsequently admitted to the hospital for further evaluation and management of her severe hypokalemia.

Upon admission, the patient’s hypokalemia was thought to be caused by her fludrocortisone, with a secondary differential diagnosis of adrenal insufficiency. Urine electrolytes, urine creatinine, urine...
osmolality, thyroid panel, and plasma cortisol lab studies were ordered to further elucidate the cause of the patient’s disease.

A follow-up potassium level, drawn two hours after the patient’s potassium had been repleted, was 2.4 mmol/L, unchanged from her initial level. Her potassium was again repleted with both IV and oral potassium. Her blood pressure increased to 151/77 mmHg at 8:00 am, five hours after she was admitted. It then increased to 171/82 mmHg at 11:00 am. At that time, her hypertension was treated with 5 mg of IV hydralazine, and her blood pressure decreased to 109/65 mmHg over the next several hours. The patient’s follow-up lab results showed a low plasma renin activity at <0.167 ng/mL/hr and a low aldosterone level at <1.0 ng/dL. Notably, her plasma cortisol level was normal at 11.20 mcg/dL. Her urine studies and thyroid panel results did not reveal any signs of disease.

The morning after the patient’s admission, she informed the internal medicine team that she had recently been eating large quantities of black licorice. This information, alongside the patient’s lab results, narrowed the differential diagnosis. A synergistic interaction between licorice and the fludrocortisone was now suspected as the cause of the patient’s hypokalemia. The endocrinology service was consulted and agreed with the primary team’s assessment. They recommended stopping the fludrocortisone and repleting potassium as needed.

The patient’s potassium level increased to a normal value of 3.5 mmol/L five hours after her second course of potassium repletion, roughly thirty-four hours after her last dose of fludrocortisone. She required two more administrations of 5 mg IV hydralazine to keep her systolic blood pressure below 150 mmHg.

She remained in the hospital for another night for continued observation and monitoring of her potassium. At the time of discharge, the patient’s potassium was 3.5 mmol/L, and her metabolic alkalosis had resolved. She was instructed to stop taking fludrocortisone at home, and was prescribed midodrine to treat her neurogenic orthostatic hypotension. She was informed about the dangers of combining licorice and fludrocortisone and asked to follow-up with her primary care provider for further management.

### Discussion

The renin-angiotensin-aldosterone system (RAAS) is the hormonal feedback loop responsible for regulating sodium and potassium homeostasis and fluid balance [6]. Normally, renin is released from the kidney in low-blood volume states, and its downstream effects work to maintain healthy blood pressure. One such action of renin is that it increases plasma aldosterone [7]. Aldosterone works to decrease serum potassium, increase serum sodium, and ultimately increase blood pressure [8].

Our patient’s lab values showed low renin, low aldosterone, and severe hypokalemia, along with normal plasma cortisol levels and normal urine studies. She was also intermittently hypertensive.

Importantly, our patient had also been taking fludrocortisone, a steroid medication with a similar mechanism of action to endogenous aldosterone [9]. Fludrocortisone potently decreases serum potassium levels, and can be used to treat hyperkalemia [9]. This medication contributed to the severity of our patient’s electrolyte imbalance.

Thus, the differential diagnoses for our patient revolved around etiologies of low-renin hypertension, such as Conn syndrome, Liddle’s syndrome, deficiencies of enzymes 11β-hydroxylase or 17α-hydroxylase, and AME [10].

Conn Syndrome is a disorder characterized by primary hyperaldosteronism due to an aldosterone-secreting adenoma in the adrenal gland [11]. The autonomous secretion of aldosterone suppresses plasma renin activity, resulting in low plasma renin activity. Thus, Conn syndrome is associated with an increase in plasma aldosterone, which excludes this syndrome as the cause of our patient’s disease.

Deficiencies of enzymes 11β-hydroxylase and 17α-hydroxylase are examples of congenital adrenal hyperplasias. They are caused by inherited defects in CYP11B1 and CYP17 genes, which encode the corresponding enzymes, and are passed down in an autosomal recessive pattern [12]. Both conditions result in a decrease in serum cortisol level. Deficiency of 17-alpha hydroxylase is accompanied by an increase in mineralocorticoids, while 11-beta hydroxylase deficiency is characterized by decreased aldosterone levels and a decrease in plasma renin activity [12]. While these enzyme deficiencies have a clinical presentation and several lab values consistent with our patient’s presentation, her plasma cortisol level was normal, while the hallmark of these diseases is low cortisol. Additionally, the age of onset would be highly unusual for these genetic diseases.

Patients with Liddle’s syndrome present with hypertension due to inherited mutations in the epithelial Na+ channel (ENaC) in the collecting tubules of the kidney [13]. This disease is characterized by abnormal urine studies: increased urinary potassium excretion, decreased urinary sodium excretion, low rate of urinary aldosterone excretion, and a low ratio of aldosterone to potassium [14]. Clinically, Liddle’s syndrome mimics
hyperaldosteronism, however, serum plasma aldosterone levels are severely decreased [14]. Our patient’s
normal urine studies made Liddle’s syndrome an unlikely culprit.

AME is a genetic disease that results from the inability of the enzyme 11β-hydroxysteroid dehydrogenase to
convert cortisol to inactive cortisone [15]. With this enzyme malfunctioning, plasma cortisol is able to bind
to the mineralocorticoid receptor with the same affinity as aldosterone, while circulating with a magnitude
of 1000–2000 times greater than aldosterone [16]. This results in a clinical presentation of hypertension and
hypokalemia at a young age [17]. Additionally, due to feedback inhibition, the endogenous renin–
angiotensin–aldosterone system is suppressed, which leads to low renin and aldosterone levels [17].

Licorice produces symptoms that mirror AME, and should also be considered as a differential diagnosis
(Table 1). Glycyrrhizic acid, a by-product of licorice metabolism, inhibits the peripheral conversion of
cortisol to the inactive cortisone [18]. This results in a hypermineralocorticoid clinical presentation, as
cortisol binds to mineralocorticoid receptors with the same affinity as aldosterone, but is present in the
bloodstream at a far higher concentration compared to aldosterone [18]. Thus, given our patient’s age of
presentation, lab values, and licorice consumption, her presentation was most consistent with hypertension
with an etiology of an AME caused by chronic licorice ingestion and exacerbated by her simultaneous use of
steroid medications [19].

| Disease                         | Serum Potassium | Plasma Renin Activity | Plasma Aldosterone Levels | Plasma Cortisol Levels |
|--------------------------------|-----------------|-----------------------|---------------------------|------------------------|
| Conn Syndrome                  | ↓ / Normal      | ↓                     | ↑                         | Normal                 |
| 11β-hydroxylase deficiency     | ↓               | ↓                     | ↓                         | ↓                      |
| Apparent Mineralocorticoid Excess | ↓              | ↓                     | ↓                         | Normal                 |

**TABLE 1: Differential Diagnosis**

Due to the rarity of our patient’s condition, there is little evidence-based medicine to guide the management
of her multifactorial etiology of hypertension. The first steps we took in her treatment course were to treat
her severe hypokalemia with potassium supplementation and discontinue her mineralocorticoid medication.
We monitored her potassium closely while the etiology of her hypokalemia was being investigated. On
discharge, we discontinued her steroid medication and prescribed her an alternative treatment for her
neurogenic hypotension. We also provided our patient with extensive education about the dangers of
consuming licorice in such high quantities.

Prior documented cases of licorice-induced hypertension have been successfully treated with
mineralocorticoid receptor antagonists (ex. spironolactone) and other potassium-sparing diuretics (ex. amirolide) [20]. After large quantity licorice consumption, RAAS may remain suppressed for as long as three
months. Thus, follow-up electrolyte studies and close monitoring of blood pressure is recommended [20].

This article was previously presented as a virtual poster at the 2020 Nevada American College of Physicians
Chapter Abstracts Competition—Southern Region on October 20, 2020.

**Conclusions**

The biggest takeaway lesson from our case is how important it is to take a detailed patient history. The
etiology of our patient’s disease hinged on one specific, seemingly insignificant detail about her diet. It is
essential that health care providers take the time to thoroughly discuss dietary habits and lifestyle choices
with their patients, as it could reveal the underlying cause of their disease. Our patient’s case also presents
an opportunity to appreciate the plethora of etiologies of severe hypokalemia. From medications to genetic
diseases and excessive candy consumption, the sheer number of causes can be overwhelming. As illustrated
in the above case, medications and diet can be a significant, even synergistic, source of severe electrolyte
derangement. Although it may not be considered initially, lifestyle and diet changes are often present and
may contribute to life-threatening diseases.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained by all participants in this study. **Conflicts of interest:** In
compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services
info:** All authors have declared that no financial support was received from any organization for the
submitted work. **Financial relationships:** All authors have declared that they have no financial
relationships at present or within the previous three years with any organizations that might have an
interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Shibata S: A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi. 2000, 120:849-862. 10.1248/yakushi1947.120.10.849
2. Bush TM, Rayburn K, Holloway SW, et al.: Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey. Altern Ther Health Med. 2007, 15:30-35.
3. Farese RV Jr, Biglieri EG, Shackleton CHL, Irony I, Gomez-Fontes R: Licorice-induced hypermineralocorticidism. N Engl J Med. 1991, 325:1223-1227. 10.1056/NEJM199110243251706
4. Deutch MR, Grimm D, Wehland M, Infanger M, Krüger M: Bioactive candy: effects of licorice on the cardiovascular system. Foods. 2019, 8:495. 10.3390/foods8100495
5. Nazari S, Rameshbad M, Hosseinazadeh H: Toxicological effects of Glycyrrhiza glabra (licorice): a review. Phytotherapy research. 2017, 31:1635-1650. 10.1002/pttr.25893
6. Monticone S, Losano I, Tetti M, Buffolo F, Veglio F, Mulatero P: Diagnostic approach to low-renin hypertension. Clin Endocrinol (Oxf). 2018, 89:385-396. 10.1111/cen.13741
7. Baudrand R, Vaidya A: The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor. J Mol Sci. 2018, 19:546.
8. Xu N, Hirohama D, Ishizawa K, et al.: Hypokalemia and pendrin induction by aldosterone. Hypertension. 2017, 69:855-862. 10.1161/HYPERTENSIONAHA.116.08519
9. Athimulam S, Lazik N, Bancos I: Low-renin hypertension. Endocrine Hypertension, An Issue of Endocrinology and Metabolism Clinics-E-Book. Elsevier Health Sciences, 2019. 48:701-715.
10. Ganguly A: Primary aldosteronism. N Engl J Med. 1998, 339:1828-1834. 10.1056/NEJM199812173392507
11. White PC: Inherited forms of mineralocorticoid hypertension. Hypertension. 1996, 28:927-956. 10.1161/01.HYP.28.6.927
12. Abriel H, Loffing J, Rebhun JF, et al.: Defective regulation of the epithelial Na⁺ channel by Nedd4 in Liddle’s syndrome. J Clin Invest. 1999, 104:667-673.
13. Botero-Velez M, Curtis JJ, Warnock DG: Liddle’s syndrome revisited—a disorder of sodium reabsorption in the distal tubule. N Engl J Med. 1994, 330:178-181. 10.1056/NEJM199401203300305
14. Palermo M, G Delitala, Mantero F, Stewart PM, Shackleton CHL: Congenital deficiency of 11β-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): Diagnostic value of urinary free cortisol and cortisone. J Endocrinol Invest. 2001, 24:27-13. 10.1007/BF03543803
15. Tapia-Castillo A, Baudrand R, Vaidya A, et al.: Clinical, biochemical, and genetic characteristics of "nonclassic" apparent mineralocorticoid excess syndrome. J Clin Endocrinol Metab. 2019, 104:595-605. 10.1210/jc.2018-01197
16. Edwards CRW, Walker BR, Benediktsson R, Seckl JR: Congenital and acquired syndromes of apparent mineralocorticoid excess. J Steroid Biochem Mol Biol. 1993, 45:1-5. 10.1016/0960-0760(93)90114-C
17. Heikens J, Fliers E, Endert E, Ackermans M, van Montfrans G: Liquorice-induced hypertension—a new understanding of an old disease: case report and brief review. Neth J Med. 1995, 45:230-234. 10.1016/0300-2977(95)90005-S
18. Jones ES, Spence JD, McIntyre AD, et al.: High frequency of variants of candidate genes in black Africans with low renin-resistant hypertension. Am J Hypertens. 2017, 30:478-483. 10.1093/ajh/hpw167
19. Foster CA, Church KS, Poddar M, Van Uum SHM, Späic T: Licorice–induced hypertension: a case of pseudohyperaldosteronism due to jelly bean ingestion. Postgrad Med. 2017, 129:329-331. 10.1080/00325481.2017.1291062
20. Marfo K, Glücklich D: Fludrocortisone therapy in renal transplant recipients with persistent hyperkalemia. Case Rep Transplant. 2012, 586859. 10.1155/2012/586859